Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) received a drug registration certificate for its alendronate sodium oral solution issued under the authority of China's National Medical Products Administration, a Friday Hong Kong bourse filing said.
The drug is suitable for the treatment of osteoporosis in postmenopausal women to
prevent hip and spinal fractures and in men to increase bone mass.